# Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

> **NCT07553767** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Ningbo No.2 Hospital** · enrollment: 156 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- HEPATITIS B CHRONIC
- Hepatitis B Chronic Infection

## Interventions

- **DRUG:** Peginterferon alfa-2b
- **DRUG:** TDF
- **DRUG:** TAF
- **DRUG:** TMF

## Key facts

- **NCT ID:** NCT07553767
- **Lead sponsor:** Ningbo No.2 Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2034-12-31
- **Final completion:** 2035-12-31
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07553767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07553767, "Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07553767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*